Efficacy and Safety of Vorolanib Monotherapy As Third-line or Later Treatment for Advanced Non-small Cell Lung Cancer Patients: a Single-arm, Prospective, Open-label Phase II Clinical Study

This Phase II study is testing vorolanib, an oral targeted therapy that blocks blood vessel growth in tumors, as a late-line treatment option for people with advanced non-small cell lung cancer (NSCLC) who have already tried at least two prior treatments. **You may be eligible if...** - You have confirmed advanced or metastatic NSCLC - You have already received at least two rounds of systemic cancer treatment (or cannot tolerate chemotherapy) - You are in reasonably good health (ECOG 0-2) and expected to live at least 3 months - Your blood counts, kidney, and liver function meet required levels - Your cancer does not have a targetable gene mutation, OR if it does, you have already been treated with the relevant targeted therapy **You may NOT be eligible if...** - You previously received a multi-target anti-angiogenic drug (like anlotinib or apatinib) - You have small cell lung cancer - You have active bleeding, unhealed wounds, or recent major surgery - You have had a blood clot, stroke, or serious heart or liver problem - You are pregnant, breastfeeding, or planning pregnancy - You have an active or uncontrolled infection, HIV, or hepatitis Talk to your doctor to see if this trial is right for you.